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For predicting genetic risk, we propose a statistical approach that is specifically adapted to dealing with the challenges imposed by
disease phenotypes and case-control sampling. Our approach (termed Genetic Risk Scores Inference [GeRSI]), combines the power of
fixed-effects models (which estimate and aggregate the effects of single SNPs) and random-effects models (which rely primarily on
whole-genome similarities between individuals) within the framework of the widely used liability-threshold model. We demonstrate
in extensive simulation that GeRSI produces predictions that are consistently superior to current state-of-the-art approaches. When
applying GeRSI to seven phenotypes from the Wellcome Trust Case Control Consortium (WTCCC) study, we confirm that the use of
random effects is most beneficial for diseases that are known to be highly polygenic: hypertension (HT) and bipolar disorder (BD).
For HT, there are no significant associations in the WTCCC data. The fixed-effects model yields an area under the ROC curve (AUC)
of 54%, whereas GeRSI improves it to 59%. For BD, using GeRSI improves the AUC from 55% to 62%. For individuals ranked at the
top 10% of BD risk predictions, using GeRSI substantially increases the BD relative risk from 1.4 to 2.5.Introduction
Despite the huge investment and considerable progress in
the study of the genetic causes of human diseases, the
underlying genetic mechanisms of many common dis-
eases, including type 1 diabetes (T1D), bipolar disorder
(BD), schizophrenia, multiple sclerosis, and Alzheimer dis-
ease, are still largely unknown. The leading methodology
for finding the genetic causes of disease is the genome-
wide association study (GWAS). In a typical GWAS, one
collects thousands of sick and healthy individuals, geno-
types them, and searches for SNPs that are more abundant
in one group or the other. To date, GWASs have flagged
thousands of SNPs as associated with hundreds of diseases.
However, our ability to accurately predict an individual’s
disease status on the basis of these SNPs still falls consider-
ably short of what is expected given the high heritability of
these diseases.
This remarkable gap between the predictive power of
significantly associated SNPs and the expected predictive
capacity based on the high heritability of the phenotypes
has been termed the ‘‘mystery’’ or ‘‘problem’’ of the
missing heritability. One leading theory attempting to
explain this mystery is that many phenotypes are driven
by a plethora of common SNPs with small effects and
that present-day GWASs are underpowered to detect these
SNPs because of their small effects. Goldstein1 estimated
the overall number of SNPs affecting height at 93,000.
In light of this theory, the traditional naive approach of
using only the SNPs found to be significantly associated
with the disease in calculating genetic-risk scores (GRSs)
is expected to perform poorly because it overlooks the
lion’s share of causal SNPs, whose effect is not large enough
to be declared significant. Instead, recent efforts in
computing GRSs have attempted to include a larger num-1Department of Statistics, Tel Aviv University, Tel Aviv 69978, Israel
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The Americber of SNPs, primarily by adopting much more lenient
inclusion criteria for SNPs.
Using a more permissive threshold has two effects: (1)
capturing more ‘‘true’’ causal signal through the inclusion
of causative SNPs with small effects and (2) increasing the
noise in the genetic prediction, given that every additional
parameter estimated (for either a true association or a false-
positive signal) adds uncertainty to the predictions. A good
choice of p value threshold would be such that the trade-
off between signal and noise is beneficial. Recent studies
have demonstrated that GRSs computed in this manner
have a significant association with disease—one above
and beyond that of GRSs computed with only significantly
associated SNPs—when up to half of the genotyped SNPs
are included (see, e.g., Purcell et al.2). These results suggest
that for at least some diseases, there is considerable infor-
mation in the long tail of insignificantly associated SNPs
and that the benefit from including more true positives
trumps the cost of estimating more parameters. Dud-
bridge3 and Chatterjee et al.4 provide an in-depth mathe-
matical analysis of this approach and variants thereof,
and it was recently applied to predicting risk of Celiac dis-
ease with remarkable success.5
These approaches for computing GRSs fall under the
category known in the statistics literature as ‘‘fixed-effects’’
modeling. In such models, the effects of SNPs are assumed
to be parameters (i.e., fixed but unknown quantities).
These parameters are estimated and used in subsequent
analysis. For example, one would estimate the odds ratio
of a given SNP from a GWAS and use this estimate to pre-
dict the risk of new individuals. The main difference be-
tween the methods lies in the way these parameters are
estimated, ranging from simple SNP-by-SNP regression to
shrinkage-based estimates, such as Lasso and more, as re-
viewed by Dudbridge3 and Abraham et al.5 They also differ4305, USA
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in the way SNPs are chosen to be included in computation
of the risk scores.3,5 However, they all share the funda-
mental treatment of the effects as parameters that require
estimation.
An alternative approach to computing GRSs is ‘‘random-
effects’’ modeling. The basic premise of this approach is
that our goal is not to estimate the individual effect of
every SNP but rather to estimate their cumulative effect.
Hence, it is expected to be beneficial to circumvent esti-
mating each and every effect and instead target this cumu-
lative effect directly. To accomplish this goal, effect sizes
are treated not as parameters but rather as random vari-
ables with some common distribution. They can then be
‘‘integrated out,’’ thus mitigating the need to estimate
them separately. Instead, a correlation (or kinship) matrix
G is estimated with the genotypes and models the correla-
tions between the GRSs. The correlation between GRSs of
individuals who are more genetically similar would be
higher, and vice versa.
This random-effects approach has been adopted in the
context of GWASs for association tests6–10 and heritability
estimation11–14 withmuch success. All of these approaches
rely on treating the phenotype as a normally distributed
variable, which is the sum of a genetic component and
an environmental component, and utilizing well-estab-
lished linear-mixed-model (LMM) methodologies to draw
inferences about their quantities of interest.
In the context of risk prediction, the animal-breeding
literature has long used similar approaches to model and
estimate the ‘‘breeding value,’’ which is closely related
to the genetic risk. In the scenario of an observational
study of a quantitative phenotype, a well-established
methodology for estimating the breeding value is known
as the best linear unbiased predictor, or BLUP.15,16 When
breeding values are estimated, pedigree data are usually
available. In GWASs, the kinship can be estimated from
genotype data (referred to as genetic BLUP, or gBLUP17),
and this method is implemented in the widely used
GCTA software.18 It was recently extended in various
ways,19,20 resulting in a considerable improvement in pre-
diction accuracy.
However, case-control studies present amuchmore chal-
lenging statistical setup. First, the phenotype is binary
rather than quantitative and so cannot be accurately
modeled by a multivariate normal (MVN) distribution.
Additionally, affected individuals (cases) are highly over-
represented in the sample, in comparison to the popula-
tion, and so many of the typical statistical assumptions
(namely normality and independence of the genetic and
environmental effects) are no longer legitimate.
A common approach to random-effects modeling in
case-control GWASs is to treat the phenotype as quantita-
tive and apply LMM methodologies, possibly followed by
post-hoc corrections to account for violation of the under-
lying assumptions.12,13,19 Although this approach has
proven successful in practice, its reliance on probabilistic
models that are known to be inaccurate is expected to384 The American Journal of Human Genetics 95, 383–393, Octoberresult in suboptimal performance. In the context of GRS
estimation, the natural extension of the LMM approach
to case-control data is to use gBLUP and its extensions,
but this is subject to similar inaccuracy concerns, as our
simulations below demonstrate.
We describe a statistical approach for Genetic Risk
Scores Inference (GeRSI). GeRSI is based on a Markov-
chain Monte-Carlo (MCMC) method utilizing Gibbs
sampling to estimate the GRSs of individuals given the
genotypes of a case-control study under a random-effects
model. We use the well-known normal liability-threshold
model to account for the dichotomous nature of the
phenotype. Additionally, our Gibbs-sampling approach
conditions explicitly on the selection of individuals to
the study and thus accounts directly for the overrepresen-
tation of the case group in the study. By properly condi-
tioning on the selection, we can sample from the true
posterior distribution of the GRS. This is in contrast to
using LMM-based approaches, which treat a case-control
disease phenotype as if it were a randomly sampled quan-
titative one.
In addition to accounting for disease phenotypes and
nonrandom selection in prediction, GeRSI naturally ac-
commodates fixed effects within the probabilistic frame-
work. Hence, our approach also allows ‘‘mixed-effects’’
modeling, where SNPs with considerable effects can be
included as fixed effects and the long tail of insignificantly
associated SNPs is accounted for with random effects. We
distinguish between random-effects GeRSI (which treats
all SNPs as random effects) and mixed-effects GeRSI
(which, in our basic implementation, includes SNPs below
a certain p value threshold as fixed effects and treats the
rest of the SNPs as random effects). Additionally, intro-
ducing fixed effects to the model allows accounting for
additional covariates such as sex, ethnicity, and known
environmental risk factors (e.g., smoking habits). Mixed-
effects GeRSI can also utilize other schemes for selecting
fixed-effects SNPs and estimating their effects (such as
Lasso21) or including covariate effects estimated from
published data.22 Hence, it can combine state-of-the-art
approaches for fixed-effects estimation with proper infer-
ence on random effects.Material and Methods
Generative Model of a Polygenic Disease
A polygenic quantitative trait y is typically modeled with the
following additive model:
yi ¼ mþ
X
j˛C
zijuj þ ei;
where C is the set of causal SNPs, ui is the effect of the i
th causal
SNP, ei is the environmental effect associated with individual i,
and zij is the genotype of the j
th SNP of the ith individual. The
term
P
j˛Czijuj is often referred to as the genetic effect and
denoted gi. Under mild independence assumptions, we have
s2g ¼ VarðgÞ ¼ jCjs2u.2, 2014
We note that the choice to use standardized SNPs rather than
just centering the SNPs hides an implicit assumption that SNPs
with lower frequencies have larger effect sizes (as noted in Zhou
et al.13). However, because we focus on common SNPs, the effects
of this assumption are minimal.
Polygenic disease phenotypes are modeled with the liability-
threshold model.12 We assume the existence of a latent quan-
titative ‘‘liability’’ phenotype. If an individual’s liability exceeds
a certain threshold, she is part of the case group. The liability
is modeled as a quantitative trait with mean 0 and variance 1.
Under these assumptions, the threshold corresponding to
disease prevalence K is F1(1  K) ¼ Z1K, where F is the cumu-
lative distribution function of the standard normal distribution
and F1 is its inverse (percentiles of the distribution), often
denoted Z.
Random-Effects Modeling
We are interested in predicting risk, and the actual values of ui
are not of direct interest. We therefore model them as random
variables drawn from a distribution with mean 0 and variance
s2g=jCj. Typically, one assumes a normal distribution (e.g., Yang
et al.11 and Zhou et al.13), but other distributions were sug-
gested as well as mixture distributions.4,13 We note that as long
as the number of causal SNPs is large enough and the effect
sizes are independent of each other, the genetic effect approxi-
mately follows a normal distribution, regardless of the underlying
distribution of the effect sizes, by virtue of the central-limit
theorem.
Assuming normality of the random effects and random sam-
pling, this implies the following MVN distribution of the liabil-
ities: l MVNð0;Gs2g þ Is2e Þ; where G is the correlation matrix of
the genetic effects and is given by
Gij ¼ 1j C j
X
k˛C
zikzjk;
and it is assumed without loss of generality (because l is unob-
served) that s2g þ s2e ¼ 1. Given that the identity of the causal
SNPs is unknown and additionally they are often not genotyped,
we follow previous works11,12 and estimate G by using all geno-
typed SNPs and use this estimate throughout. This matrix is often
referred to as the observed kinship matrix. The estimation of G is
the subject of much recent research (see, e.g., Golan and Rosset,14
Speed et al.,23 and Crossett et al.24) but is out of the scope of the
current paper.GeRSI Sampling Scheme
Assume that we have a group of n individuals with known geno-
types but that the phenotypes are known only for the first n  1
individuals. We are interested in predicting the genetic risk of
the nth individual.
We denote g and e the vectors of latent genetic and environ-
mental effects, respectively. The heritability (and hence s2g ) is
assumed to be known and in practice can be estimated directly
from the data11,12 or obtained from family studies.
Our goal is to predict P(ln > t), conditional on our entire data
(namely the genotypes of all n individuals and the phenotypes
of the first n  1 individuals). Had we known gn, the (optimal)
risk prediction, rn, under the model would have been
rn ¼ Pðln > t j gnÞ ¼ 1F

t  gn
se

:The AmericHowever, because gn is unknown, we generate k samples,
gn,1,.,gn,k, from the posterior distribution of gn, conditional on
all the observed data, and estimate the risk as
brn ¼ 1
k
Xk
i¼1

1F

t  gn;i
se

:
To generate samples from the posterior distribution of gn, we
note that
P

gn j yn;G; s2g

¼ P

gn j gn; yn;G; s2g

P

gn j yn;G; s2g

¼ P

gn j gn;G; s2g

P

gn j yn;G;s2g

:
In other words, sampling the posterior can be decomposed into
two separate problems. The first problem is the problem of sam-
pling gn given the values of the other genetic effects, gn. Because
we are conditioning on the genetic effects, gn is independent of the
phenotypes of the other individuals.
Asweshowbelow, evenwhen the sampling isnot random(e.g., in
case-control studies), the conditional distribution of gn is given by
gn j gn;G;s2g MVN

Gn;nG
1
n;ngn; s
2
g

Gn;n Gn;nG1n;nGn;n

;
where positive or negative indices indicate the extraction or
removal, respectively, of rows or columns.
The second problem is the problem of sampling from gnjy;G;s2g ,
which is more involved. We introduce another set of variables,
namely the environmental effects en. It is then possible to write
down the conditional distribution of each variable in the set
(gn,en), conditional on the rest of the variables in the set.
The knowledge of the phenotype induces dependence between
gi and ei, given that knowing the phenotype implies that we have
an upper or lower bound on their sum (the sum is either above or
below the threshold, depending on the phenotype). Additionally,
ei is independent of the other environmental effects and is also in-
dependent of the other genetic effects conditional on gi. Hence,
ei j g; ei; yi;s2g ¼ ei j gi; yi;s2g ¼

seZ j seZ þ gi > t yi ¼ case
seZ j seZ þ gi < t yi ¼ control ;
where Z ~ N(0,1) (hence, the distribution is simply a truncated
normal distribution). Intuitively, when gi is known and the
phenotype is known, the posterior distribution of the environ-
mental effect is a truncated normal distribution withmean 0, vari-
ance s2e , and a truncation point above or below t  gi, depending
on whether i is in the case or control group.
The conditional distribution of gi is slightly more complicated
because it depends on the other genetic effects via the correlation
between genetic effects. Thus, we need to explicitly describe its
conditional distribution, conditional on the other gi genetic
effects and all environmental effects. By the independence
assumption between genetic and environmental effects, we only
need to consider dependence on ei and the other genetic effects
(gi) via the correlation between genetic effects.
Denote mi and s
2
i the mean and variance of gi, conditional
on gi, respectively. Then, mi ¼ Gi;iG1i;igi and s2i ¼ s2g ðGii
Gi;iG1i;iGi;iÞ:
Similarly to the conditional distribution of the environmental
effects, conditioning on the phenotype results in a truncation of
the aforementioned normal distribution:
gi j ei; gi; yi;s2g ¼

mi þ siZ jmi þ siZ þ ei > t yi ¼ case
mi þ siZ jmi þ siZ þ ei < t yi ¼ control :an Journal of Human Genetics 95, 383–393, October 2, 2014 385
Again, the conditional distribution can be seen as a truncated
normal distribution, but with a mean term and variance term
that capture the influence of the other genetic effects on the
genetic effect in question.
Once all of the conditional distributions are specified, Gibbs
sampling25 can be used to draw samples from the posterior distri-
bution of gn, and the risk is estimated as described above. This is
done is a similar fashion to Campbell et al.26
Conditional Sampling in Case-Control Studies
The fact that the observed samples are obtained via a case-control
sampling scheme and are therefore not a random sample from the
population renders the usual mixed-effects model incompatible.
In particular, under assumptions of (1) normality of genetic and
environmental effects in the population and (2) independence
of the genetic and environmental effects in the population, the
actual distribution of genetic and environmental effects in the
study is nonnormal, and they are not independent as a result of
selection, as noted in Lee et al.12 Because the distribution of the
genetic effects is no longer normal, their joint distribution is no
longer MVN, and so naive application of Gibbs sampling might
be inaccurate. However, we show here that the same sampling
scheme can be used to sample the posterior genetic effects in a
case-control study.
To model and account for the effects of selection, we define an
event S, which signifies that individuals 1,.,n1 were selected
via a case-control scheme and not by random sampling. Hence,
the conditional distributions above now require additional condi-
tioning on S. However, we note that
f

gn j gn;S;G;s2g

¼
f

S j gn; gn;G; s2g

f

gn j gn;G;s2g

f

S j gn;G;s2g
 ;
but because S signifies only the selection of individuals 1,.,n1, it
is independent of gn. Hence, f ðSjgn; gn;G;s2g Þ ¼ f ðSjgn;G;s2g Þ and
f ðgnjgn;S;G; s2g Þ ¼ f ðgnjgn;G; s2g Þ; i.e., Gibbs sampling of the ge-
netic effect of the individual in question can be carried out as if
there were no selection, given that the samples of the genetic
effects g1,.,gn1 are drawn by correct conditioning on S. More-
over, for an individual i in the reference group, we have
f

gi j ei; gi; yi;S;s2g

¼
f

S j ei; gi; yi; gi; s2g

f

gi j ei; gi; yi;s2g

f

S j ei; gi; yi;s2g
 ;
but because we assumed that the selection is driven only
by the phenotypes, we have f ðSjei; gi; yi; s2g Þ ¼ f ðSjyi; s2g Þ and
f ðSjei; gi; yi; gi; s2g Þ ¼ f ðSjyi; s2g Þ, so again the sampling boils
down to the same Gibbs scheme. Lastly, we need to take care of
the sampling of the environmental effects, but because this is
done per individual, the selection has no effect. To conclude, the
same Gibbs sampling scheme can be applied to case-control
studies and yield correct posterior risk estimates.
Simulation Setup
Our simulations adopt the ‘‘spike-and-slab’’ model of genetic risk,
recently explored by Zhou et al.13 and Chatterjee et al.4 and found
to provide a good fit for the observed effect sizes for a wide variety
of GWASs. In this model, all SNPs have effects on the phenotype,
but the SNPs are divided into a small fraction of ‘‘slab’’ SNPs with
considerable effect sizes and a bulk of ‘‘spike’’ SNPs with very small
but nonzero effects.386 The American Journal of Human Genetics 95, 383–393, OctoberGiven the prevalence of a disease in the population (K),
the desired proportion of cases in the study (P), the desired
study size (n), the total number of SNPs (m), the proportion
of slab SNPs (p1), the overall variance of the genetic effects
(s2g ), and the fraction of the heritability explained by the slab
SNPs (fslab), we simulated data sets by using the following
procedure:
1. We randomly sampled the minor allele frequencies (MAFs)
of m SNPs from U[0.05,0.5].
2. We randomly sampled SNP effect sizes for p1m slab SNPs
and (1  p1)m spike SNPs from Nð0; fslabs2g=ðp1mÞÞ and
Nð0; ð1 fslabÞs2g=ðð1 p1ÞmÞÞ, respectively.
3. For each individual, we (a) randomly generated a genotype
by using the MAFs, (b) computed the genetic effect as
described above, (c) sampled an environmental effect from
Nð0;1 s2g Þ, (d) computed liability and phenotype, and (e)
if the phenotype was in the case group, automatically
included the individual in the study. Otherwise, we
included the individual in the study with probability
K(1  P)/(P(1  K)) to maintain the expected proportion
of cases in the study at P.
4. We repeated steps 2 and 3 until n individuals were accumu-
lated.
Setting fslab ¼ 1 results in a model where only p1 of the SNPs
are causal and the rest of the SNPs have no effects on the
phenotype.
We note that our choice of working with SNPs in linkage equi-
libriumwasmotivated by a result of Patterson et al.27 They showed
that for the purpose of generating correlationmatrices, using SNPs
in linkage disequilibrium (LD) is equivalent to using a smaller
number of SNPs in linkage equilibrium. They also suggested a
method for estimating the effective number of SNPs (i.e., the num-
ber of SNPs in linkage equilibrium that lead to the same distribu-
tion of correlation matrices as a given set of SNPs in LD). We
thus find that our simulations using m ¼ 50,000 SNPs in equilib-
rium are of realistic size.
Computing GRSs with ‘‘Standard’’ Fixed-Effects
Models
To compute GRSs with a fixed-effects approach, we follow the
spirit of Dudbridge3 and Chatterjee et al.4 For each SNP, we esti-
mate the effect size bu by using univariate linear regression. Denote
by vi the p value of the null hypothesis of ui ¼ 0. We then define
the estimated risk score by using a p value threshold c as
risk score ðcÞj ¼
XbuiZijIfvi < cg:
When dealing with real data, where LD structure is present, we
select a subset of significant SNPs—such that the distance be-
tween included SNPs is at least 1 Mb—by choosing the SNP
with the lower p value within any such window. We note that
other alternative definitions exist, e.g., using shrinkage estimates,
but generally there is very little difference between the methods,
as noted by Dudbridge.3 For the real data, we try several p value
thresholds, namely 5 3 10c for c˛f1;.;8g. We then choose the
threshold that maximizes the area under the ROC curve (AUC).
Hence, AUC estimates of the fixed-effects model are expected to
be slightly elevated. Our bootstrap scheme for computing confi-
dence intervals accounts for this selection scheme, as detailed
below.2, 2014
Random- and Mixed-Effects GeRSI
We use the genotyped SNPs to estimate the genetic correlation
matrix G. When applying random-effects GeRSI, we use this
matrix as the correlation matrix in the sampling scheme described
above. When applying mixed-effects GeRSI with a p value
threshold c, we keep only SNPs with a p value below that threshold
in the univariate association test.We then use logistic regression to
estimate the personal in-study risk due to the fixed effects. We
then convert this risk to the liability scale by using the following
transformation:
bt i ¼ F
 
1 C
bPi
1þ CbPi  bPi
!
;
where bPi is the estimated in-study risk, bt i is the individual-specific
liability threshold, and C ¼ K(1  P)/(P(1  K)). We note that this
method is reminiscent of the method of Zaitlen et al.22 but differs
in the data utilized for estimating the covariate effects, given that
Zaitlen et al.22 take advantage of external data for this purpose.
gBLUP
For comparison, we compute the gBLUP by coding the discrete
phenotype as 0/1 and treating it as a quantitative and randomly
sampled phenotype. In other words, the phenotype is modeled as
y MVNð0;SÞ;
where S ¼ Gs2g þ Is2e . Hence, if the phenotype of individual i is
unknown, then the conditional mean of her phenotype is easily
obtained with the formula for the conditional mean of a MVN
distribution:
E
h
yi j yi;S; s2g
i
¼ Si;iS1i;iyi:
The gBLUP method could be similarly extended to account for
fixed effects (see, e.g., Yang et al.18).
Extending to Multiple Correlation Matrices
Recently, Speed and Balding19 extended gBLUP to account for
multiple correlationmatrices (‘‘multiBLUP’’). The SNPs are divided
into k subsets according to some criteria (e.g., functional annota-
tion), and correlationmatricesG1,.,Gk are estimated for each sub-
set separately. The corresponding variances of the effect sizes,
s2g1 ;.;s
2
gk
, are either estimated or taken from published sources,
as before. This formulation allows SNPs from different sets to
have a typically larger or smaller effect on disease risk. The corre-
lation of the genetic effect is then given by
Gmulti ¼
Xk
i¼1
Gis
2
gi
:
MultiBLUP is defined as running gBLUP with Gmulti instead of the
previously definedG. We similarly extend GeRSI to ‘‘multi-GeRSI,’’
i.e., running random-effects GeRSI with Gmulti.
Controlling for Population Structure
When attempting to control for population structure in associa-
tion studies or heritability estimation, it is customary to include
several top principal components as covariates. However, in the
context of risk prediction, this would result in inflated estimates
of the predictive accuracy. Instead, we remove the top k principal
components directly from the correlation matrix. In other words,
denote l1,.ln the sorted eigenvalues of the correlation matrix GThe Americand denote v1,.,vn their corresponding eigenvectors. We define
a cleaned correlation matrix as
GðkÞ ¼ G
Xk
i¼1
liviv
u
i :
Describing Real Data
We obtained genotypes and phenotypes from the Wellcome Trust
Case Control Consortium (WTCCC). Following Lee et al.12 we
applied a stringent quality-control (QC) process to the WTCCC
data to avoid overestimation of the predictive capacity due to gen-
otyping differences between case and control groups or between
the different control groups. We removed SNPs with a MAF <
5%, SNPs with a missing rate > 1%, and SNPs that displayed a
significantly different missing rate between case and control
groups (p value < 0.05). We also removed SNPs that deviated
from Hardy-Weinberg equilibrium in the control groups
(p value < 0.05) or were noted for ‘‘bad clustering’’ in the geno-
type-calling step. Additionally, we removed SNPs that displayed
a significant difference in frequency between the two control
groups. Only autosomal chromosomes were included in the anal-
ysis. We removed all the individuals appearing in the WTCCC
exclusion lists. These included duplicate samples, first- or
second-degree relatives, individuals not of European descent,
and other reasons. In addition, we removed individuals with a
missing rate > 1% and all individual pairs with an estimated
genetic correlation < 0.05 according to the correlation matrix.
We performed the last step to ensure that individuals in the study
were not closely related. In addition, when computing the correla-
tionmatrixG, we used estimatedMAFs fromHapMap’s CEU panel
(Utah residents with ancestry from northern and western Europe
from the CEPH collection)28 to mitigate any possibility of leakage
between the train and test sets. Our approach requires specifica-
tion of population parameters of each disease (prevalence and her-
itability), and we detail the parameters we used and their sources
in Table S1, available online.
Inference
We use the bootstrap29 to estimate the SD of our AUC estimates by
resampling the GRSs or genetic-risk predictions. For GeRSI, this is a
straightforward bootstrap scheme. Denote AUC(r1,.,rn,y1,.,yn)
the estimated AUC given risk predictions r1,.,rn (obtained via
the method described above) and phenotypes y1,.,yn. We sample
with return n indices i1,.,in ˛ {1,.,n}. The jth bootstrap AUC
sample is then
AUCj ¼ AUC

ri1 ;.; rin ; yi1 ;.; yin

;
and we report the empirical SD of 100 such bootstrap samples.
When dealing with fixed-effects models, we must account for the
fact that the p value threshold is selected on the basis of the AUC.
Obtained with c as a threshold, the risk score of the ith individual,
is denoted rci . A bootstrap sample accounting for threshold selec-
tion is thus given by
AUCj ¼max
c
n
AUC

rci1 ;.; r
c
in
; yi1 ;.; yin
o
:
Lastly, when testing whether one method performs better than
another, we note that comparing AUCs by using estimated SDs
is considerably conservative, given that AUCs obtained with the
same set of observations are expected to be highly correlated.an Journal of Human Genetics 95, 383–393, October 2, 2014 387
Fixed effects Fixed effects Fixed effects
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Figure 1. Comparison of the Perfor-
mance of Fixed-, Random-, and Mixed-
Effects Models in Predicting Disease Risk
in a Spike-and-Slab Model
Wesimulatedbalanced case-control studies
of a disease with 5% prevalence and 50%
heritability and for which the fraction of
slab SNPs with large effects was either 1%
or 10% out of a total of 50,000 simulated
SNPs and for which these slab SNPs ac-
counted for 90% of the heritability, in line
with values from Chatterjee et al.4 We
show the performance of the fixed-effects
approach with (A) a Bonferroni-adjusted
p value threshold, (B) a p value threshold
of 0.05, and (C) a p value threshold of 0.5.
In addition, we computed the correlation
matrix G and used it to predict risk with
the random-effects GeRSI approach, as
well as with mixed-effects GeRSI treating
the SNPs from (A) as fixed effects. In each
simulation, we used a train set of 3,000 in-
dividuals and estimated the AUC for each
method by using a test set of 1,000 individ-
uals. We used the results from 20 indepen-
dent simulations to draw the box plots.Instead, we follow a similar scheme to estimate the SD of the dif-
ference in AUC directly.Estimating Relative Risk
We are interested in estimating the relative risk (RR) of individuals
at the top X of the risk predictions. A subtle aspect is that we wish
to do so with case-control data because we don’t have a random
sample from the population. For a given risk threshold v, we esti-
mate the fraction of the population with risk predictions higher
than this threshold as
ppop ¼ K
ncases
X
yi¼case
Ifri > vg þ 1 K
ncontrols
X
yi¼control
Ifri > vg:
We then search for a value v such that ppop is the desired value.
The fraction of cases with risk predictions higher than the
threshold is pcases ¼ ð1=ncasesÞ
P
yi¼1Ifri > vg, and the RR is esti-
mated as pcases/(1  pcases) 3 (1  ppop)/ppop.Results
We tested GeRSI in extensive simulations, as described in
the Material and Methods. Prediction quality is measured
by the AUC, which is the probability that a randomly
sampled affected individual (case) attains a higher GRS
than a randomly sampled unaffected individual (control).
Our results demonstrate, as expected, that fixed-effects
modeling is generally effective when the phenotype is
driven by a small number of SNPs with sizable effects
(i.e., most causal SNPs are easily identified) and that the
random-effects approach is most effective when the
phenotype is driven by a large number of SNPs with small
effects. Mixed-effects GeRSI performs well in both sce-
narios, as well as in intermediate scenarios, and was never
inferior to fixed-effects modeling or gBLUP in any of our
simulations.388 The American Journal of Human Genetics 95, 383–393, OctoberIn Figure 1, we present the results for the spike-and-slab
model of genetic risk, recently explored by Zhou et al.4 and
Chatterjee et al.13 and described in the Material and
Methods. The results illustrate the power and flexibility
of GeRSI and its superior performance in comparison to
fixed-effects modeling (superior in all 20 simulation runs;
for both setups, p value < 106 with sign tests). When
slab effects were relatively small (as in the bottom panel),
random-effects GeRSI and mixed-effects GeRSI performed
similarly, but in the presence of large slab effects (as in
the top panel), the mixed-effects version allowed us to
capture these as fixed effects and was far superior to the
random-effects version. The results for other simulation
settings are presented in Figures S1–S21.
In Figure 2, we compare GeRSI to gBLUP, which similarly
utilizes random-effects modeling to reduce the number of
parameters. Here, too, GeRSI’s performance was uniformly
superior, as expected from the fact that it utilizes the cor-
rect probabilistic model rather than an approximated
model. We also investigated the recently described
multiBLUPmethod of Speed and Balding,19 which extends
the BLUP model to include several variance components.
We did this by constructing two correlation matrices in
our spike-and-slab model—one for the spike SNPs and
one for the slab SNPs. Using this refined correlation struc-
ture yielded considerably more accurate results. Impor-
tantly, GeRSI can be similarly extended to accommodate
several variance components (multi-GeRSI), thus taking
advantage not only of the refined correlation structure
but also of GeRSI’s improved statistical-modeling
approach. As expected, multi-GeRSI outperformed multi-
BLUP in our simulations (Figure 2). Lastly, multi-GeRSI
can be extended to incorporate fixed effects (mixed
multi-GeRSI) so that SNPs with remarkably significant
effects are treated as fixed effects while the rest aremodeled2, 2014
Figure 2. Comparison of the Perfor-
mance of BLUP andGeRSIMethods in Pre-
dicting Disease Risk in a Spike-and-Slab
Model
We compared the performance of BLUP,
multiBLUP, GeRSI, multi-GeRSI, and
mixed multi-GeRSI by using the same
simulation setup as in Figure 1. We
observed that GeRSI outperformed BLUP
by utilizing the correct probabilistic setup.
MultiBLUP takes into account the different
effect-size distributions of spike and slab
SNPs and therefore outperformed both.
Multi-GeRSI enjoys the best of both
worlds—correct sampling scheme and
improved correlation structure—and so
trumped all previous methods. Lastly,
mixed multi-GeRSI improves over multi-
GeRSI by including the most significant
SNPs as fixed effects in addition to the
other advantages of the multi-GeRSI
approach.as random effects. This approach improved the perfor-
mance even further (Figure 2).
We then proceeded to apply GeRSI to seven WTCCC30
case-control studies on BD, coronary artery disease
(CAD), Crohn disease (CD), hypertension (HT), T1D,
type 2 diabetes (T2D), and rheumatoid arthritis (RA). For
each phenotype, we first performed stringent QC as sug-
gested by Lee et al.12 and detailed in the Material and
Methods to mitigate batch effects. We then estimated the
AUC with 4-fold cross-validation by using both the fixed-
effects method of Dudbridge3 and the random-effects
and mixed-effects GeRSI approaches. To demonstrate the
potential clinical utility of the risk-prediction approaches
examined, we also estimated the RR of an individual found
to be in the top 1% and 10% of risk predictions. For the
fixed-effects approaches, we considered a range of possible
p value thresholds (5 3 10c for c˛f1;.;8g) and display
here the best result for each phenotype.
Comparing the fixed-effects approach to random-effects
GeRSI, we observed that random-effects GeRSI obtained
significantly higher AUC than the optimized fixed-effects
approach for four of the seven phenotypes: BD, T2D,
CAD, andHT (p value< 109, 103, 103, and 105, respec-Table 1. Comparison of the Fixed-Effects Approach and Random-Effe
Phenotype
Fixed
Best Threshold AUC (SE) RR a
BD 0.5 0.55 (0.01) 1.4
T2D 0.005 0.55 (0.01) 1.48
CAD 5 3 105 0.65 (0.01) 1.85
HT 0.5 0.54 (0.01) 1.31
The AUC and RR of the top 10% and top 1% of individuals were estimated by 4-f
effects GeRSI approach to the predictions obtained by a fixed-effects approach. W
thresholds (53 10c for c ˛ {1,.,8}) and display here results for the value with the
as a covariate. CI stands for confidence interval.
The Americtively; Table 1; see the Material and Methods for details).
Specifically for HT, no SNPs were found to be associated
at the 5 3 108 genome-wide-significance level in the
WTCCC data,30 and very few associations have been found
in any studies to date (only seven associations are listed in
the NHGRI GWAS Catalog [see Web Resources]). The
optimal p value threshold for the fixed-effects model was
0.5, indicating a true polygenic architecture and thus an
ideal phenotype for random-effects modeling. As ex-
pected, random-effects GeRSI yielded substantially better
predictive power with an AUC around 0.6 and a consider-
able increase in RR for individuals at the top 10% of GeRSI
risk predictions (1.61 versus 1.31). Figure 3 contrasts the
ROC curves and the risk-prediction behavior of the two
approaches on HT data.
Contrary to HT, BD has numerous replicated associa-
tions, some of which were identified in the original
WTCCC study. However, in agreement with other
studies,2 we found that using a permissive p value
threshold for risk predictions is appropriate (the optimal
p value threshold was 0.5). Here, too, using random-effects
modeling was beneficial, as expected. This is reflected in
the AUC and 10% RR numbers in Table 1. Additionally,cts GeRSI on Four Phenotypes from the WTCCC
Random
t Top 10% [CI] AUC (SE) RR at Top 10% [CI]
[1.03–1.65] 0.62 (0.01) 2.5 [2.16–2.96]
[1.2–1.83] 0.59 (0.01) 1.67 [1.34–1.99]
[1.17–2.3] 0.67 (0.01) 2.16 [1.79–2.72]
[1.06–1.55] 0.60 (0.01) 1.61 [1.42–1.97]
old cross-validation. We compared the predictions obtained from our random-
e computed the AUC of the fixed-effects approach for a wide range of p value
highest AUC (note that GeRSI has no such parameter). All analyses included sex
an Journal of Human Genetics 95, 383–393, October 2, 2014 389
Figure 3. Comparison of HT Risk Predictions with Fixed-Effects Models and Random-Effects GeRSI
We used the fixed-effects approach with a p value threshold of 0.5. With fixed effects, there is very little difference between the distri-
bution of risk scores of cases and control (top-left panel), but with random-effects GeRSI, out-of-sample risk predictions for cases is clearly
skewed to the right (bottom-left panel). This is also evident in the comparison of the ROC curves of both methods (right panel).the top 1% of risk scores attained a RR of almost 4 in
random-effects GeRSI but only 1.26 with the fixed-effects
approach.
Random-effects GeRSI did not improve over fixed-effects
modeling for CD and performed significantly worse for RA
and T1D (Table 2). This is consistent with our knowledge
regarding the genetic architecture of these diseases: all
three are autoimmune diseases with strongly associated
SNPs with considerable effect sizes, primarily in the MHC
region on chromosome 6. Gusev et al.31 recently showed
that a significant portion of the heritability of these dis-
eases is due to variants in the vicinity of previously identi-
fied causal SNPs and is not uniformly distributed along the
genome. To demonstrate the flexibility of mixed-effects
GeRSI to combine the power of fixed- and random-effects
modeling, we also show its performance in Table 2, where
it is generally comparable to that of the fixed-effects
approach (slightly superior for CD, p value < 103).Discussion
An important aspect in applying prediction methodology
to case-control data is that of population structure. It is
well established that population structure must be ac-
counted for in GWASs, and this is often done with mixed
models8 or by inclusion of several top principal compo-
nents as covariates.32 In the context of heritability estima-
tion, population structure can inflate the estimated
heritability if unaccounted for, and typically a number of
principal components of G are included as fixed effects390 The American Journal of Human Genetics 95, 383–393, Octoberto control for that structure. During risk prediction, the
role of population structure is more complicated. We
distinguish between two types of population structure:
actual and induced. Actual population structure is struc-
ture that is truly present in the population and is properly
reflected in the study group. Importantly, taking advantage
of this type of structure for the purpose of risk prediction is
legitimate, even if the effect of the structure on the pheno-
type is not via genetics. For example, if the diet of individ-
uals of a certain ethnicity affects their disease risk, but this
is not accounted for with fixed effects (e.g., if dietary infor-
mation is not collected), this can still be captured in GeRSI
via the genetic differences between these individuals and
others in the population.
On the other hand, induced structure is an artifact of
the sampling procedure. For example, a certain sub-
population might be considerably more likely to be
sampled as cases rather than controls. In this case, GeRSI
predictive-power estimates based on the study sample
might be illegitimately inflated if this structure is not
accounted for.
The WTCCC studies are considered to have relatively
little structure,30 and we are not able to separate the struc-
ture that does exist into its legitimate and induced compo-
nents. To examine the robustness of our results to removal
of structure, we reran our analyses while removing the top
ten principal components from the correlation matrix
(Table 3). This had a small negative effect on the perfor-
mance of GeRSI for some of the phenotypes, such as BD
and RA, but the general spirit of the results remained
unchanged.2, 2014
Table 2. Comparison of the Random- and Mixed-Effects GeRSI Approach and the Fixed-Effects Approach for Three Autoimmune Diseases
in the WTCCC Data
Phenotype
AUC (SE) RR at Top 10% [CI]
Fixed Random Mixed Fixed Random Mixed
CD 0.59 (0.01) 0.59 (0.01) 0.62 (0.01) 2.02 [1.67–2.34] 2.18 [2.12–2.53] 2.63 [2.32–2.81]
T1D 0.72 (0.01) 0.55 (0.01) 0.71 (0.01) 3.4 [3.19–3.63] 1.46 [1.31–1.83] 3.45 [2.76–3.57]
RA 0.67 (0.01) 0.63 (0.01) 0.68 (0.01) 2.85 [2.62–3.61] 1.83 [1.44–2.07] 2.93 [2.55–3.54]
The AUC and RR of the top 10% of individuals were estimated by 4-fold cross-validation. We compared the predictions obtained from our random-effects GeRSI
approach, our mixed-effects GeRSI approach, and a fixed-effects approach. We computed the AUC of the fixed-effects approach and the mixed-effects GeRSI
approach for a wide range of p value thresholds (5 3 10c for c ˛ {1,.,8}) and display here results for the value with the highest AUC. All analyses included
sex as a covariate. CI stands for confidence interval.Another key point is that of QC. Following Lee et al.,12
we applied very stringent QC as described in the Material
and Methods. Such stringent QC is particularly important
during the evaluation of predictions, given that different
cohorts are genotyped at different times and different
centers, and so systematic genotyping errors might mani-
fest as inflated estimates of the predictive capacity. On
the other hand, stringent QC results in fewer SNPs and
fewer individuals in the inspected data sets, which could
result in conservative estimates of the predictive power.
The major computational bottleneck in GeRSI is the
computation of the genetic correlation matrix (time
complexity of Oðn2mÞ, where n is the number of individ-
uals in the reference sample and m is the number of
SNPs). However, it is very easy to parallelize this task, and
the correlations for the reference panel could be computed
offline. Additionally, faster implementations of correla-
tion-matrix computations could be utilized for improved
performance.33 The second bottleneck is the inversion of
the correlation matrix for the purpose of computing the
conditional means and variances (time complexity of
Oðn3Þ). This task could also be completed for the reference
set offline, and rank-one updates could be used once the
correlations between the reference set and the new individ-Table 3. Investigating the Possible Effect of Sampling-Induced
Population Structure on Estimating Accuracy of Risk Prediction
Phenotype
AUC (SE) RR at Top 10% [CI]
0 PCs 10 PCs 0 PCs 10 PCs
BD 0.62 (0.01) 0.59 (0.01) 2.5 [2.3–3.05] 1.81 [1.66–2.23]
CD 0.59 (0.01) 0.57 (0.01) 2.18 [1.83–2.55] 1.74 [1.49–2.01]
T1D 0.55 (0.01) 0.52 (0.01) 1.46 [1.09–1.7] 1.03 [0.94–1.16]
T2D 0.59 (0.01) 0.57 (0.01) 1.67 [1.58–1.8] 1.66 [1.46–1.76]
CAD 0.67 (0.01) 0.68 (0.01) 2.16 [1.75–2.61] 2.5 [2.24–2.93]
RA 0.63 (0.01) 0.6 (0.01) 1.83 [1.47–1.91] 1.77 [1.45–1.97]
HT 0.59 (0.01) 0.6 (0.01) 1.61 [1.48–1.91] 1.68 [1.46–1.85]
We compared the AUCs and RRs for the top 10% of individuals when using the
correlation matrix G directly or after removing the top ten principal compo-
nents (PCs) as described in the Material and Methods. As expected, we
observed a minor decrement in performance in some phenotypes, but others
(such as CAD and HT) displayed no real change in performance. All analyses
included sex as a covariate. CI stands for confidence interval.
The Americual are computed. Lastly, the time complexity of the Gibbs
sampling itself is linear in the number of individuals. In
conclusion, if proper prepossessing is carried offline, the
time complexity of predicting the risk of a newly observed
genotype is OðnmÞ. Our main simulations used a reference
set of 3,000 individuals to predict the phenotype of 1,000
individuals, in which case the three parts—computing the
correlation matrix, inverting the matrix, and predicting
risk—were completed in approximately 2 hr, 20 min, and
2 min, respectively, with a single core of a standard laptop
computer. Our implementation is available in the Web
Resources.
To study the scalability and performance of GeRSI
when larger reference panels are used, we repeated the
simulations of Figure 1 with reference panels of 6,000 or
9,000 individuals (Figures S22 and S23). For the largest
studies simulated, the entire simulation and prediction
process took about 2 days with a single CPU with 16 GB
RAM. As expected, the performance of all methods
improved as the size of the reference panel increased,
but qualitatively, the results remained the same. Impor-
tantly, mixed-effects GeRSI still outperformed all other
methods.
In conclusion, GeRSI is a method that takes advantage of
the full power of random-effects modeling to accumulate
evidence from the entire genome for the purpose of ob-
taining accurate risk predictions from GWASs. This is
accomplished through an appropriate probabilistic-infer-
ence approach, also allowing for inclusion of relevant fixed
effects, including associated SNPs and other covariates.
Thus, any method for selecting a subset of SNPs or esti-
mating covariate effects for the purpose of fixed-effects
modeling can be used to model the fixed part of GeRSI
and gain power from treating the rest of the SNPs as
random effects.3,4,21,22,34,35 Our results demonstrate the
significant benefits of using this approach on both simu-
lated and real data. Additionally, approaches designed for
predicting quantitative phenotypes and that already uti-
lize random effects could be easily adapted to take advan-
tage of the GeRSI sampling scheme when applied to
case-control data and benefit from a more accurate proba-
bilistic model. We have demonstrated the improvement in
performance for BLUP and multiBLUP, but similar im-
provements can be expected for other methods designedan Journal of Human Genetics 95, 383–393, October 2, 2014 391
for predicting quantitative phenotypes by using both fixed
and random effects (e.g., LMM-Lasso20).
Specifically for BD, random-effects GeRSI allows us to
identify 1% of the population at 4-fold risk of disease
and 10% of the population at 2.5-fold risk. These numbers
represent a major improvement over current state-of-the-
art approaches and bring us closer to the ultimate goal of
obtaining clinically useful risk predictions from GWAS
data. We believe that random-effects modeling is a key
component in this quest.Appendix A
Matrix Identities for Fast Computation of the
Conditional Mean and Variance
This section contains some matrix identities that are used
in the software for faster computation.
Let x MVNðm;SÞ. We are interested in the conditional
distribution xijxi. It is well known that for the MVN case,
it is given by
xi j xiN

Si;iðSi;iÞ1ðxi  miÞ;Sii  Si;iðSi;iÞ1Si;i

:
We wish to quickly compute the mean and variance
for every i. Naively, this implies inverting an (n  1) 3
(n  1) matrix for n individuals in the train set, resulting
in running-time complexity of o(n4), which is infeasible
for realistic values of n. We are therefore interested in
computing the conditional mean and variance for every
individual in a more effective fashion.
To do so, focusing on i ¼ n WLOG, we write
S ¼

A b
cu d

and S1 ¼

E f
gu h

;
where A and E are (n 1)3 (n 1) matrices, so b, c, f, and g
are column vectors, and d and h are scalars.
The first result is
A1 ¼ E fg
u
h
(for a derivation, see Mathematics Stack Exchange in the
Web Resources). In other words, the inverses of all prin-
cipal submatrices can be computed from the inverse of
the overall matrix.
However, we are not interested directly in A1 but rather
in the conditional mean and variance.
The conditional mean is given by Si;iðSi;iÞ1ðxi
miÞ, so all we need to compute is Si;iðSi;iÞ1, in other
words,
cuA1 ¼ cu

E fg
u
h

¼ cuE c
ufgu
h
¼
 dgu  ð1 dhÞg
u
h
¼ g
u
h
;
where we use the identities cuE þ dgu ¼ 0 and cuf þ
dh ¼ 1, which stem from the identity SS1 ¼ I.392 The American Journal of Human Genetics 95, 383–393, OctoberWith our notation, the variance is
Sii  Si;iðSi;iÞ1Si;i ¼ d  cuA1b ¼ d  cu

E fg
u
h

b:
Again, using the fact that cufþ dh¼ 1 and cuEþ dgu¼ 0,
we get
. ¼ d  cu

E fg
u
h

b ¼ d 

cuE c
ufgu
h

b ¼ d


 dgu  ð1 dhÞg
u
h

b ¼ d þ g
u
h
b ¼ d
þ 1 dh
h
¼ 1
h
:
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